Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Issue 8 (August 2018)

• Record Type: Journal Article
• Authors: Federico, Massimo; Caballero Barrigón, María Dolores; Marcheselli, Luigi; Tarantino, Vittoria; Manni, Martina; Sarkozy, Clementine; Alonso-Álvarez, Sara; Wondergem, Marielle; Cartron, Guillaume; Lopez-Guillermo, Armando; Issa, Djamila; Morschhauser, Franck; Alcoceba, Miguel; Kimby, Eva; Rusconi, Chiara; Chamuleau, Martine; Holte, Harald; Lockmer, Sandra; Montoto, Silvia; Gomes da Silva, Maria; Aurer, Igor; Zucca, Emanuele; Paszkiewicz-Kozik, Ewa; Minoia, Carla; Skrypets, Tetiana; Blaker, Yngvild Nuvin; Salles, Gilles; Coiffier, Bertrand
• Is Part Of: Lancet. Volume 5:Issue 8(2018)
• Page Start: e359
• Page End: e367
• Publication Date: 2018-08
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15005
• DOI: 10.1016/S2352-3026(18)30090-5
• Languages: English
• ISSNs: 2352-3026

Abstract

Summary: Background: Histological transformation of follicular lymphoma to aggressive lymphoma is a serious event with a substantial effect on patient outcome. The aim of the Aristotle study was to assess the effect of rituximab on the risk of histological transformation and its outcome. Methods: 11 cooperative groups or institutions across Europe contributed data to this study. Eligible patients (≥18 years) had histologically confirmed follicular lymphoma grade 1, 2, or 3a, diagnosed between Jan 2, 1997, and Dec 20, 2013. Histological transformation was defined as a biopsy-proven aggressive lymphoma that occurred as a first event after first-line therapy. The primary endpoints were the cumulative hazard of histological transformation and survival after transformation. Findings: Information was available for 10 001 patients with follicular lymphoma, 8116 of whom were eligible for analysis. 509 histological transformations were reported. After a median follow-up of 87 months (range 1–221; 2·5–97·5th percentile 5–160), the 10-year cumulative hazard of histological transformation was 7·7% (95% CI 6·9–8·5). The 10-year cumulative hazard of histological transformation was 5·2% (95% CI 4·5–6·2) in patients who received rituximab and 8·7% (7·2–10·6) in those who did not (hazard ratio [HR] 0·73, 95% CI 0·58–0·90; p=0·004). The 10-year cumulative hazard of histological transformation was 5·9% (95% CI 5·0–7·0) for patients who received induction rituximab only and 3·6% (95% CI 2·3–5·5) for those treated with induction and maintenance rituximab (HR 0·55, 95% CI 0·37–0·81; p=0·003). This finding was confirmed in a multivariate analysis (p=0·016). 287 deaths were recorded in 509 patients with histological transformation, resulting in a 10-year survival after transformation of 32% (95% CI 26–38). Survival after transformation did not differ between patients not exposed to rituximab and those who received rituximab in induction only (HR 0·94, 95% CI 0·69–1·28; p=0·70), and those who received rituximab in induction and maintenance (0·96, 0·58–1·61; p=0·88). Interpretation: The risk of histological transformation as a first event can be significantly reduced by the use of rituximab. These findings support the need to inform patients using rituximab nowadays that the risk of transformation is lower than it was before the introduction of rituxumab. Funding: Associazione Angela Serra per la Ricerca sul Cancro, European Lymphoma Institute, European Hematology Association Lymphoma Group, Fondazione Italiana Linfomi, Spanish Group of Lymphoma and Bone Marrow Transplantation.